Navigation Links
Pure Transplant Solutions Launches Crowdfunding Campaign for Its Novel Technology Poised to Change the Future of Organ Transplantation

Austin, Texas (PRWEB) July 25, 2013

Pure Transplant Solutions, LLC (PTS) a biotechnology start-up company looking to revolutionize the future of transplantation medicine, has launched a campaign on the crowdfunding site,, to raise awareness and development funds of $100,000 in 45 days for its proprietary, selective Antibody Removal Column (the ARCTM). The ARC is a medical device that filters and selectively removes harmful antibodies from an organ recipient’s blood to allow an organ of a non-matched donor to be transplanted into the recipient, without the usual risk of organ rejection. The name of the PTS Indiegogo campaign is "Any Organ Any Body".

According to the Organ Procurement and Transplantation Network (OPTN), it is estimated that over 215,000 Americans die yearly from diseases that are treatable by transplant. Each day, an average of 79 people receive a transplant, but on that same day, an average of 18 people die waiting for one. The length of time a person has to wait for a transplant depends on many things but is primarily determined by the degree of matching between a person and a donor.

More than 80% of US transplant candidates are waiting for kidneys. One third of patients waiting for a kidney are considered to be “highly sensitized” meaning they have high levels of harmful antibodies and may never be matched with a donor no matter how long they are on the waiting list.

The ARC directly addresses this issue by allowing living donors to donate a kidney. “This technology would make it possible for the people who care most, to donate their organ to those they love most, but with whom they do not match for tissue type; with less reliance on the organ banks,” said Dr. Gina Lento, PTS Vice President. “The ARC not only decreases the risk of organ rejection, but is also much safer than existing treatments since it doesn’t strip the blood of all antibodies and proteins, only those that don’t match with a donor.”

The ARC can be used to treat any kind of solid organ or bone marrow transplant recipient, but as with most innovations in transplant medicine, new treatments are tried in kidney transplantation first since kidney transplants are the most frequent and have the highest survival rates.

With the ARC technology, organ transplantation will become an option for those patients who have been unable to find a donor match based on their highly sensitized condition. Long-term survival rates and quality of life of patients will increase as the frequency of organ rejection episodes decrease. The ARC will also decrease the time patients have to wait for an organ, and it will significantly impact the donor organ pool by making organs available regardless of tissue match.

“There are hundreds of thousand of people globally that could benefit from the ARC technology and we believe a crowdfunding campaign is the best way to get the word out about its potential,” said Dr. William Hildebrand, PTS Founder and Chief Scientist.

Indiegogo is the world's largest self-serve open-funding platform offering rewards in exchange for contributions. For as little as $5, a pledge can be made to help advance the ARC technology and become a part of transplantation history. Other perks include a limited edition “Any Organ Any Body” t-shirt and an autographed copy of The Climb of My Life the true story of world-renowned mountain climber and heart transplant recipient, Kelly Perkins. A larger contribution secures two tickets to an exclusive event in Austin, TX where contributors will meet the scientific team, enjoy food, drink and live music by nine-time Grammy winner and lead singer of Asleep at the Wheel, Ray Benson, and other Texas musicians yet to be announced.

View the Indiegogo campaign at Follow it on Twitter: and Facebook:

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, L.L.C. (“PTS”) was founded in 2003 by Dr. William Hildebrand, Presbyterian Health Foundation Endowed Professor and the Robert Glenn Rapp Foundation Presidential Professor in the Department of Microbiology and Immunology at The University of Oklahoma Health Sciences Center. Dr. Hildebrand and his team have created a game-changing immunotherapeutic combination medical device for use in a novel selective antibody removal therapy based on thirteen years of expertise in HLA production and application development. This immunotherapeutic device called the HLA-ARCTM (or simply the ARC) is a selective HLA Antibody Removal Column that has the ability to selectively remove only those anti-HLA antibodies that are deleterious to the individual’s transplanted organ or bone marrow. PTS is a subsidiary of Pure Protein L.L.C, a company that has developed and patented several soluble HLA protein technology methods. Visit for more information.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. SynCardia Total Artificial Heart Bridges Mother of Four with Congenital Heart Defect & Biventricular Heart Failure to Transplant
2. Universal Stem Cell Product Could Overcome Key Challenges in Donor Organ Transplants
3. SynCardia Total Artificial Heart Bridges Former Semi-Pro Arena Football Player to Heart Transplant
4. Researchers identify signals that direct the immune system to reject a transplanted organ
5. Stem cell transplant restores memory, learning in mice
6. Stem cells produce compact, regenerated bone in mandible transplants
7. Transplanted brain cells in monkeys light up personalized therapy
8. Stem Cells Show Promise in Extending Transplanted Kidneys’ Survival Time
9. University of Kentucky Medical Center Transplants States 1st SynCardia Total Artificial Heart Patient
10. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
11. The PROOF Centre of Excellence Partners with OriGene Technologies on Heart & Kidney Transplant Biomarker Program
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Park Systems , world ... scanning ion conductance microscopy module to Park NX10 that is the only product ... SICM benefits virtually all materials characterization that require measurements in liquid such as ...
(Date:12/1/2015)... Texas (PRWEB) , ... December ... ... , a leading relationship marketing company specializing in scientifically backed, age-defying products, ... January 2016 issue, which highlights the exponential success and unrivaled opportunities that ...
(Date:12/1/2015)... Calif. , Dec. 1, 2015 Cepheid ... of its participation at the Piper Jaffray Healthcare Conference ... this morning, the Company is reaffirming its outlook for ... for 2016, in addition to discussing longer term business ... and Chief Executive Officer.  "We continue to be the ...
(Date:12/1/2015)... ... December 01, 2015 , ... The American Society of Gynecologic ... Kyle Mathews will join fellow surgeons in the shared pursuit of “advancing ... experienced urogynecologist, founder of Plano Urogynecology Associates and Fellow of the American ...
Breaking Biology Technology:
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... JOLLA, Calif. , Oct. 29, 2015  The ... a new report titled, "DNA Synthesis and Biosecurity: Lessons ... well the Department of Health and Human Services guidance ... issued in 2010. --> ... but it also has the potential to pose unique ...
Breaking Biology News(10 mins):